[1] |
Cheadle, J.P., Reeve, M.P., Sampson, J.R. et al. Molecular genetic advances in tuberous sclerosis Hum. Genet., 107 (2000),pp. 97-114
|
[2] |
Crone, S.A., Zhao, Y.Y., Fan, L. et al. ErbB2 is essential in the prevention of dilated cardiomyopathy Nat. Med., 8 (2002),pp. 459-465
|
[3] |
Dazert, E., Hall, M.N. mTOR signaling in disease Curr. Opin. Cell Biol., 23 (2011),pp. 744-755
|
[4] |
Frey, N., Katus, H.A., Olson, E.N. et al. Hypertrophy of the heart: a new therapeutic target? Circulation, 109 (2004),pp. 1580-1589
|
[5] |
Hershberger, R.E., Cowan, J., Morales, A. et al. Progress with genetic cardiomyopathies: screening, counseling, and testing in dilated, hypertrophic, and arrhythmogenic right ventricular dysplasia/cardiomyopathy Circ. Heart Fail., 2 (2009),pp. 253-261
|
[6] |
Hershberger, R.E., Morales, A., Siegfried, J.D. Clinical and genetic issues in dilated cardiomyopathy: a review for genetics professionals Genet. Med., 12 (2010),pp. 655-667
|
[7] |
Kobayashi, T., Minowa, O., Sugitani, Y. et al. Proc. Natl. Acad. Sci. USA, 98 (2001),pp. 8762-8767
|
[8] |
Kwiatkowski, D.J., Zhang, H., Bandura, J.L. et al. Hum. Mol. Genet., 11 (2002),pp. 525-534
|
[9] |
Malhowski, A.J., Hira, H., Bashiruddin, S. et al. Hum. Mol. Genet., 20 (2011),pp. 1290-1305
|
[10] |
Ma, A., Wang, L., Gao, Y. et al. Hum. Mol. Genet., 23 (2013),pp. 693-705
|
[11] |
Marin, T.M., Keith, K., Davies, B. et al. J. Clin. Invest., 121 (2011),pp. 1026-1043
|
[12] |
Maron, B.J., McKenna, W.J., Danielson, G.K. et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for practice guidelines J. Am. Coll. Cardiol., 42 (2003),pp. 1687-1713
|
[13] |
Mcmullen, J.R., Sherwood, M.C., Tarnavski, O. et al. Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload Circulation, 109 (2004),pp. 3050-3055
|
[14] |
Meikle, L., McMullen, J.R., Sherwood, M.C. et al. Hum. Mol. Genet., 14 (2005),pp. 429-435
|
[15] |
Northrup, H., Krueger, D.A., International Tuberous Sclerosis Complex Consensus Group Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 international tuberous sclerosis complex consensus conference Pediatr. Neurol., 49 (2013),pp. 243-254
|
[16] |
Shaaya, E.A., Hirshberg, J.S., Rabe, O.T. et al. Cardiac fat-containing lesions are common in tuberous sclerosis complex Am. J. Med. Genet. A, 161 (2013),pp. 1662-1665
|
[17] |
Smythe, J.F., Dyck, J.D., Smallhorn, J.F. et al. Natural history of cardiac rhabdomyoma in infancy and childhood Am. J. Cardiol., 66 (1990),pp. 1247-1249
|
[18] |
Thoreen, C.C., Chantranupong, L., Keys, H.R. et al. A unifying model for mTORC1-mediated regulation of mRNA translation Nature, 485 (2012),pp. 109-113
|
[19] |
Wilde, A.A., Behr, E.R. Genetic testing for inherited cardiac disease Nat. Rev. Cardiol., 10 (2013),pp. 571-583
|
[20] |
Zhang, D., Contu, R., Latronico, M.V. et al. MTORC1 regulates cardiac function and myocyte survival through 4E-BP1 inhibition in mice J. Clin. Invest., 120 (2010),pp. 2805-2816
|
[21] |
Zhu, Y., Pires, K.M., Whitehead, K.J. et al. Mechanistic target of rapamycin (mTOR) is essential for murine embryonic heart development and growth PLoS ONE, 8 (2013),p. e54221
|